Literature DB >> 20582533

Hypoxia and hypoxia inducible factors in cancer stem cell maintenance.

Zhizhong Li1, Jeremy N Rich.   

Abstract

Hypoxia promotes tumor progression through multiple mechanisms including modifying angiogenesis, metabolism switch and invasion. Hypoxia inducible factors (HIFs), particularly HIF1α and HIF2α, are key mediators in cancer hypoxia response and high expression levels of HIFs correlate with a poor prognosis in various tumor types. Cancer stem cells (CSCs), also known as cancer initiating cells or tumor propagation cells, are neoplastic cells that could self-renewal, differentiate as well as initiate tumor growth in vivo. Cancer stem cells are believed to be the key drivers in tumor growth and therapy resistance. Hypoxia has been shown to help maintain multiple normal stem cell population but its roles in cancer stem cells were largely unknown. Our group and other researchers recently identified that hypoxia is also a critical microenvironmental factor in regulating cancer stem cells' self-renewal, partially by enhancing the activity of stem cell factors like Oct4, c-Myc and Nanog. The effects of hypoxia on cancer stem cells seem to be primarily mediated by HIFs, particularly HIF2α. HIF2α is highly expressed in cancer stem cells in gliomas and neuroblastomas and loss of HIF2α leads to significant decrease in cancer stem cell proliferation and self-renewal. These findings illustrated a new mechanism through which oxygen tension and microenvironment influences cancer development. Targeting hypoxia niches may therefore improve therapy efficacy by eliminating cancer stem cell population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582533     DOI: 10.1007/82_2010_75

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  55 in total

Review 1.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

Review 2.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

3.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

Review 4.  Mitochondria as therapeutic targets for cancer stem cells.

Authors:  In Sung Song; Jeong Yu Jeong; Seung Hun Jeong; Hyoung Kyu Kim; Kyung Soo Ko; Byoung Doo Rhee; Nari Kim; Jin Han
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

5.  Cancer stem cells in glioma: challenges and opportunities.

Authors:  Jialiang Wang; Yufang Ma; Michael K Cooper
Journal:  Transl Cancer Res       Date:  2013-10-01       Impact factor: 1.241

Review 6.  Tackling the cancer stem cells - what challenges do they pose?

Authors:  Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

7.  Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids.

Authors:  T Rosenberg; M Thomassen; S S Jensen; M J Larsen; K P Sørensen; S K Hermansen; T A Kruse; B W Kristensen
Journal:  CNS Oncol       Date:  2015

8.  Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Authors:  Dou Yu; Omar F Khan; Mario L Suvà; Biqin Dong; Wojciech K Panek; Ting Xiao; Meijing Wu; Yu Han; Atique U Ahmed; Irina V Balyasnikova; Hao F Zhang; Cheng Sun; Robert Langer; Daniel G Anderson; Maciej S Lesniak
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 9.  The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors.

Authors:  Wataru Kimura; Hesham A Sadek
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 10.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.